Comparative Pharmacology
Head-to-head clinical analysis: DUREZOL versus IHEEZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUREZOL versus IHEEZO.
DUREZOL vs IHEEZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell migration and cytokine release.
Iheezo (phentolamine ophthalmic solution) is an alpha-adrenergic antagonist that inhibits sympathetic tone to the iris dilator muscle, preventing mydriasis and facilitating pupil constriction during ocular surgery.
1 drop of 0.1% ophthalmic solution in the affected eye(s) four times daily for up to 14 days.
1 drop in the affected eye(s) 3 times daily as needed for relief of ocular discomfort. For optimal use, administer at least 10 minutes apart from other ophthalmic medications.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours in adults; prolonged to 24–36 hours in hepatic impairment.
The terminal elimination half-life of proparacaine is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, resulting in a very short duration of systemic exposure.
Renal excretion of unchanged drug accounts for 30% of clearance; biliary/fecal elimination accounts for 60%, with the remainder as metabolites.
IHEEZO (proparacaine) is predominantly metabolized by plasma esterases; less than 5% is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid